Definium Therapeutics Inc [DFTX] stock is trading at $17.4, up 2.53%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The DFTX shares have gain 13.13% over the last week, with a monthly amount glided 30.83%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Definium Therapeutics Inc [NASDAQ: DFTX] stock has seen the most recent analyst activity on October 13, 2025, when Needham initiated its Buy rating and assigned the stock a price target of $28. On January 28, 2025, Evercore ISI initiated with a Outperform rating and assigned a price target of $23 on the stock. Chardan Capital Markets started tracking the stock assigning a Buy rating and suggested a price target of $20 on December 20, 2024. ROTH MKM started tracking with a Buy rating for this stock on July 24, 2024, and assigned it a price target of $36. In a note dated May 29, 2024, Robert W. Baird initiated an Outperform rating and provided a target price of $27 on this stock.
Definium Therapeutics Inc [DFTX] stock has fluctuated between $4.70 and $18.12 over the past year. Currently, Wall Street analysts expect the stock to reach $36 within the next 12 months. Definium Therapeutics Inc [NASDAQ: DFTX] shares were valued at $17.4 at the most recent close of the market. An investor can expect a potential return of 106.9% based on the average DFTX price forecast.
Analyzing the DFTX fundamentals
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Definium Therapeutics Inc’s Current Ratio is 3.30. Also, the Quick Ratio is 3.30.
Transactions by insiders
Recent insider trading involved Karlin Daniel, Chief Medical Officer, that happened on Dec 26 ’25 when 5600.0 shares were sold. Chief Executive Officer, Barrow Robert completed a deal on Dec 26 ’25 to sell 25791.0 shares. Meanwhile, Chief Legal Officer Sullivan Mark sold 11276.0 shares on Dec 26 ’25.
